Company Monitoring Page for Novartis

latest headlines for company on cafepharma

Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gap
Fierce Pharma
Wed, 07/10/19 - 11:30 am
Tags:
Novartis, Mylan, Pfizer, EpiPens, Sandoz, Symjepi, drug launches, Adamis Pharmaceuticals
Roche, Merck, Novartis and others hike prices on 83 meds starting in July: analyst
Fierce Pharma
Tue, 07/9/19 - 11:57 am
Tags:
Roche, Merck, Novartis, drug pricing
Novartis struggling to win payer coverage for $2.1M gene therapy Zolgensma: analysts
Fierce Pharma
Wed, 07/3/19 - 10:38 am
Tags:
Novartis, Zolgensma, drug pricing, SMA, gene therapy, payers
Sandoz launches oncology generic gefitinib in 13 EU countries
Pharmaceutical Business Review
Wed, 07/3/19 - 09:57 am
Tags:
Sandoz, Novartis, generics, gefitinib, metastatic non-small cell lung cancer
Novartis wraps up acquisition of Takeda’s dry eye drug Xiidra
Pharmaceutical Business Review
Tue, 07/2/19 - 10:24 am
Tags:
Novartis, Takeda, Xiidra, hdry eye disease
Swiss firm Novartis has said that it did not send chemicals that could be used to make chemical weapons to Syria
Pharmafile
Mon, 07/1/19 - 07:42 pm
Tags:
Novartis, Syria, biological weapons
Threats to Spinraza are mounting, but Biogen still has cards to play
EP Vantage
Mon, 07/1/19 - 07:25 pm
Tags:
Biogen, SMA, Spinraza, Novartis, Roche, risdiplam, Zolgensma
Novartis wins Gilenya reprieve as judge blocks generics, for now
Yahoo/Reuters
Tue, 06/25/19 - 09:20 am
Tags:
Novartis, generics, Gilenya, multiple sclerosis
Conatus Pharma to explore options as liver disease drug fails trial
Yahoo/Reuters
Mon, 06/24/19 - 07:20 pm
Tags:
Conatus Pharmaceuticals, clinical trials, NASH, emricasan, Novartis
Cost-effectiveness watchdogs skewer Novartis' MS drug Mayzent and J&J's depression spray Spravato
Fierce Pharma
Fri, 06/21/19 - 11:33 pm
Tags:
Novartis, Mayzent, JNJ, Spravato, ICER
3 Drugs Under FDA Review With Blockbuster Potential
Motley Fool
Fri, 06/21/19 - 11:24 am
Tags:
AbbVie, Upadacitinib, rheumatoid arthritis, Novartis, brolucizumab, wet age-related macular degeneration, Celgene, ozanimod, relapsing multiple sclerosis
Chutes & Ladders—Novartis says hello to new pharma chief
Fierce Biotech
Fri, 06/14/19 - 10:04 am
Tags:
Novartis, Marie-France Tschudin
The top 10 most-expensive meds in the U.S.—and they're not the usual suspects
Fierce Pharma
Thu, 06/13/19 - 12:14 pm
Tags:
drug pricing, GoodRx, Novartis, Spark Therapeutics, Zolgensma, Luxturna
Novartis Close to Settling Kickback Violations, Filing Inadvertently Shows
BioSpace
Wed, 06/12/19 - 06:40 pm
Tags:
Novartis, fraud, kickbacks, physician gifts, Medicare, Medicaid
Novartis’ Cosentyx achieves primary and secondary endpoints in psoriatic arthritis study
Pharmaceutical Business Review
Wed, 06/12/19 - 09:57 am
Tags:
Novartis, Cosentyx, clinical trials, psoriatic arthritis
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
Motley Fool
Wed, 06/12/19 - 09:45 am
Tags:
Vertex Pharmaceuticals, VX-445, tezacaftor/ivacaftor, AbbVie, upadacatinib, Daiichi Sankyo, trastuzumab deruxtecan, Celgene, liso-cel, Novartis, LY3298176
The gene therapy era has arrived. So have the challenges.
Biopharma Dive
Sun, 06/9/19 - 01:43 pm
Tags:
cell therapy, gene therapy, FDA, regulatory, Novartis, Zolgensma
A struggling Sanofi is preparing to hire Novartis senior pharma exec Paul Hudson as new CEO, replacing Brandicourt -- report
Endpoints
Thu, 06/6/19 - 11:08 pm
Tags:
Sanofi, Pharma CEOs, Novartis, Paul Hudson, Olivier Brandicourt
#ASCO19: MET inhibitors from Incyte/Novartis and Germany's Merck face off for rare subset of NSCLC patients
Endpoints
Tue, 06/4/19 - 12:16 pm
Tags:
Novartis, ASCO 2019, Incyte, MET inhibitors, capmatinib, non-small cell lung cancer
Is $2.1 million too much for a drug? For affected parents, there is no debate
Stat
Mon, 06/3/19 - 11:28 am
Tags:
Novartis, drug pricing, Zolgensma, SMA

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.